Neuropsychiatric Disorders And Treatment Market Research Report, By Disorders (Degenerative Diseases, Neurotic Disorders, Psychosis And Others), By Treatments (Shock Treatment, Drug Treatment, Others) By End Users (Hospitals, Clinics, Research Centers And Others) - Forecast Till 2030
ID: MRFR/Pharma/0773-HCR | 80 Pages | Published By Kinjoll Dey on March 2023
TABLE OF CONTENTS
1 INTRODUCTION
1.1 DEFINITION
1.2 SCOPE OF STUDY
1.2.1 RESEARCH OBJECTIVE
1.2.2 ASSUMPTIONS & LIMITATIONS
1.2.2.1 ASSUMPTIONS
1.2.2.2 LIMITATIONS
1.3 MARKET STRUCTURE:
2 RESEARCH METHODOLOGY
2.1 RESEARCH PROCESS:
2.2 PRIMARY RESEARCH
2.3 SECONDARY RESEARCH:
3 MARKET DYNAMICS
3.1 DRIVERS
3.2 RESTRAINTS
3.3 OPPORTUNITIES
3.4 MACROECONOMIC INDICATORS
4 MARKET FACTOR ANALYSIS
4.1 PORTERS FIVE FORCES MODEL
4.2 BARGAINING POWER OF SUPPLIERS
4.3 BARGAINING POWER OF BUYERS
4.4 THREAT OF NEW ENTRANTS
4.5 THREAT OF SUBSTITUTES
4.6 INTENSITY OF RIVALRY
5. GLOBAL NEUROPSYCHIATRIC DISORDERS AND TREATMENT MARKET, BY DISORDERS
5.1 DEGENERATIVE DISEASES
5.2 NEUROTIC DISORDERS
5.3 PSYCHOSIS
5.4 OTHERS
6. GLOBAL NEUROPSYCHIATRIC DISORDERS AND TREATMENT MARKET, BY TREATMENT
6.1 SHOCK TREATMENT
6.2 DRUG TREATMENT
6.3 OTHERS
7. GLOBAL NEUROPSYCHIATRIC DISORDERS AND TREATMENT MARKET, BY END USER
7.1 HOSPITALS
7.2 CLINICS
7.3 RESEARCH CENTRES
7.4 OTHERS
8. GLOBAL NEUROPSYCHIATRIC DISORDERS AND TREATMENT MARKET, BY REGION
8.1 INTRODUCTION
8.2 NORTH AMERICA
8.2.1 US
8.2.2 CANADA
8.3 EUROPE
8.3.1 WESTERN EUROPE
8.3.1.1 GERMANY
8.3.1.2 FRANCE
8.3.1.3 ITALY
8.3.1.3 SPAIN
8.3.1.5 UK
8.3.1.6 REST OF WESTERN EUROPE
8.3.2 EASTERN EUROPE
8.4 ASIA
8.4.1 JAPAN
8.4.2 CHINA
8.4.3 INDIA
8.4.4 AUSTRALIA
8.4.5 REPUBLIC OF KOREA
8.5 REST OF ASIA-PACIFIC
8.6 MIDDLE EAST & AFRICA
9. COMPETITIVE LANDSCAPE
9.1 MAJOR STRATEGIES ADOPTED BY MARKET PLAYERS
9.1.1 STRATEGIC PARTNERSHIP
9.1.2 MERGER & ACQUISITION
10 COMPANY PROFILE
10.1 ASTRAZENECA
10.1.1 OVERVIEW
10.1.2 PRODUCT OVERVIEW
10.1.3 FINANCIALS
10.1.4 KEY DEVELOPMENTS
10.2 GLAXOSMITHKLINE
10.2.1 OVERVIEW
10.2.2 PRODUCT OVERVIEW
10.2.3 FINANCIALS
10.2.4 KEY DEVELOPMENTS
10.3 UNIVERSAL HEALTH SERVICES INC
10.3.1 OVERVIEW
10.3.2 PRODUCT OVERVIEW
10.3.3 FINANCIALS
10.3.4 STRATEGY
10.3.5 KEY DEVELOPMENT
10.4 BOEHRINGER INGELHEIM GMBH
10.4.1 OVERVIEW
10.4.2 PRODUCT OVERVIEW
10.4.3 FINANCIALS
10.4.4 KEY DEVELOPMENTS
10.5 ELI LILLY
10.5.1 OVERVIEW
10.5.2 PRODUCT OVERVIEW
10.5.3 FINANCIALS
10.5.4 KEY DEVELOPMENTS
10.6 OTHERS
11 CONCLUSION
11.1 KEY FINDINGS
11.1.1 FROM CEO’S VIEWPOINT
11.1.2 UNMET NEEDS OF THE MARKET
11.2 KEY COMPANIES TO WATCH
11.3 PREDICTION OF INDUSTRY
12 APPENDIX
